THERAPEUTIC AGENT FOR DILATED CARDIOMYOPATHY

• Main Authors: KURATA HAYATO, MIYAGAWA SHIGERU, SAWA YOSHIKI, KAJITA DAISUKE, TAMADA KOTOE, NISHIDA HIROYUKI
• Format: Patent
• Language: English; Japanese
• Published: 26.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients.SOLUTION: The present invention provides a therapeutic agent for dilated cardiomyopathy comprising at least one selected from a group consisting of mesenchymal stem cells and microparticles derived from the mesenchymal stem cells. It is preferable that the mesenchymal stem cells are cells having ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.SELECTED DRAWING: None 【課題】本発明は、拡張型心筋症ＤＣＭの治療において優れた効果を奏し、かつ多くの患者に対して一定の効果が得られる拡張型心筋症疾患治療剤を提供することを目的とする。【解決手段】本発明は、間葉系幹細胞及び間葉系幹細胞由来の微小粒子からなる群より選択される少なくとも１種を含有する、拡張型心筋症治療剤である。間葉系幹細胞は、微小粒子を含有又は分泌する能力を有する細胞であること、上記微小粒子はその平均粒子径が１，０００ｎｍ以下であること、エクソソームであることが好ましい。【選択図】なし